Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Day (September 2014)
37 slides from Elekta Ab Class B's investor day presentation, Sep 15, 2014
Slide 1: Elekta Capital Markets Day
Elekta Capital Markets Day 15 September 2014, San Francisco
Slide 2: ASTRO Capital Markets Day
Elekta Capital Markets Day, San Francisco 09.00 Elekta - Strategic Agenda Niklas Savander, President and CEO 09.20 Elekta Software Todd Powell, EVP Elekta Software 09.40 Elekta North America Jay Hoey, EVP Elekta North America 10.00 Elekta Brachytherapy John Lapré, EVP Elekta Brachytherapy 10.20 Q&A
Slide 3: ASTRO 2014; Delivering on growth strategy
ASTRO 2014 ● 11,000 attendees ● 360 oral presentations Elekta’s focus at ASTRO ● 1,000 at the users meeting • Software solutions • Versa HD™ • Leksell Gamma Knife® 3 Delivering on growth strategy • Innovation − Good progress with MRI-guided linear accelerator − Strong Versa HD™ uptake • Program for
Slide 4: Cancer patients and growth factors
33 million cancer patients in the world 10,000 linear accelerator gap to meet today’s need 5 Source: Globocan 2012. Within 5-year of diagnosis Growth factors • Cancer incidence growth and re-treatments Market growth rate of • Increasing utilization of radiotherapy • Closing the gap in emerging • Sie
Slide 5: Recent financial developments; Financial objectives
Recent financial developments • Mixed market development • Elekta achieved strong order bookings: +12%* • Q1 is the seasonally smallest quarter − Net sales -4%* − Weak revenues in North America, mainly software − Cash flow 7 * Compared to last fiscal year based on constant exchange rates Financial o
Slide 6: Strategic choices; Strategic agenda for growth
Strategic choices • Emerging markets • Product innovation • Software 9 Strategic agenda for growth Innovation Leadership Grow the Pie Customers Commercial Lifecycle Transformation Management Patients 10 5
Slide 7: US market dynamics; Information-guided cancer care
US market dynamics 11 Elekta introduces Information-guided cancer care™ • Involved patient • Fully-informed care team • Increased efficiency and better outcomes • Consistent information flow across locations • Real time and data-driven quality management and performance 12 6
Slide 8: Elekta Software
Elekta Software Todd Powell Executive Vice President Elekta Software 13 Today’s cancer care challenges “I want to quickly see how a patients treatment is “I need to maximize progressing.” machine utilization.” “I want to understand toxicity curves.” “I want personalized care.” “I want to reduce pati
Slide 9: Vision: Information-guided cancer care
Patients driving change • Patients challenging health system • Closer link between the patient and the specialist • Technology adoption 15 Vision: Information-guided cancer care™ Better information will transform cancer care. 16 8
Slide 10: Elekta Software Solutions; Software innovation focus
Elekta Software Solutions Treatment planning, delivery, and assessment tools Treatment Management Clinical and practice management tools Care Knowledge Management Management Clinical and business intelligence applications 17 Software innovation focus • User-centered design • Automated decision suppo
Slide 11: Information Management: MOSAIQ; Integrating Treatment Planning
Information Management: MOSAIQ® • Stereotactic localization integration • Enhanced integrated imaging • Expanded workflow customization • Charting and practice management enhancements • Patient portal enhancements • New connectivity interfaces • Support for Phase 2 Meaningful Use 19 Integrating Trea
Slide 12: Monaco 5; Elekta Knowledge Management
Monaco® 5 21 Elekta Knowledge Management • Healthcare Analytics − Clinical, Operational and Financial Dashboards − Comparative Benchmarking • Registries − METRIQ® − Leksell Gamma Knife® Registry • Oncology Imaging Management − MOSAIQ® Data Director 22 11
Slide 13: Elekta Cloud Solutions; Region North America
Elekta Cloud Solutions • Increasing demand for cloud-based deployment • IT-managed solutions expansion for 2015 • 10% of METRIQ® users are in the cloud | Worry free | | Cost effective | | Clinically reliable | Optimize performance Control costs and better Recover quickly with and scale your practice
Slide 14: North America socio-economic factors and market dynamics
North America – socio-economic factors impact on RT Number of new cancer cases Estimated usage of radiation therapy Thousands (incl. re-treatment) 3 500 3 000 2 500 USA 63% 2 000 1 500 Canada 33% 1 000 500 Mexico 15% 0 2012 2015E 2020E 2025E 2030E 2035E • Cost-efficient • Population growth • Clinica
Slide 15: USA drivers; North America order bookings and market share
USA – drivers US health care Elekta opportunity Patient Reduce cost Efficient solutions Protection Improve quality & Safe solutions Increase access Affordable Quantitative results Care Act 27 North America - order bookings up ~7%* Q1 YoY FY15 - 14 Market share – installed base Market share – new ord
Slide 16: Leksell Gamma Knife Perfexion; MOSAIQ one platform
Leksell Gamma Knife™ Perfexion® • Growing pipeline − Confidence in the long-term underlying market − Best-of-breed focus for accountable care • System of choice at large volume brain centers − Additional high quality data supporting dose delivery superiority 29 MOSAIQ® - One platform – multiple loca
Slide 17: Elekta LINC; Awards & Recognition
Elekta LINC - Learning and Innovation Center 31 Awards & Recognition Ranks Elekta #1 vendor in Q1 2014 #1 in radiation therapy Leksell Gamma Knife® Perfexion™ 3 years in a row Top ranked OIS Elekta MOSAIQ® 4 years in a row “ It’s safe to say that if Elekta were like a typical vendor we would not hav
Slide 18: Service customer support; Elekta North America
Service customer support Driving quality and productivity • Expanding installed base shifting to Versa HD™ - average service price increase • Elekta Intellimax™ − ~80% of systems connected − ~20% of cases closed remotely 33 Elekta North America • Underlying growth of cancer patients • Consolidation
Slide 19: Elekta Brachytherapy
35 Elekta Brachytherapy John Lapré EVP Elekta Brachytherapy 36 18
Slide 20: Innovation leadership in brachytherapy; Flexitron
Innovation leadership in brachytherapy Vision 2020 Eye on the Future • System integration Elekta exhibition Commercial booth and BrachyAcademy booth • Access to brachytherapy • Adaptive combined therapy • Treatment certainty Vision 2020 Pavilion • Patient experience • Workflow efficiency 37 Flexitro
Slide 21: Esteya; Further expansion of brachytherapy
Esteya®: Addressing a new customer base • Worldwide launch • Technology • Clinical studies • Reimbursement Favorable Patient- User- procedure centric friendly time design operation 39 Further expansion of brachytherapy Positive clinical studies and focus on referring physicians • New Breast clinical
Slide 22: Focus on innovation and new indications
Oncentra® Brachy 4.5 Real-time prostate solutions Allround treatment planning for brachytherapy For HDR and LDR brachytherapy Time to focus on what counts Genuine Instant Powerful real-time sagittal adaptive Easy Reduced workflow imaging planning mapping of implant Simplified patient reconstruc- pro
Slide 23: Elekta Neuroscience; SRS/SBRT steadily growing
Elekta Neuroscience Maurits Wolleswinkel EVP Elekta Neuroscience 43 SRS/SBRT steadily growing History Outlook Steady growth of intracranial SRS/SBRT procedures will outpace SRS procedures indication growth 900 800 ~900,000 patients treated 700 with Leksell Gamma Knife® Outpatient SRS/SBRT growth rat
Slide 24: Leaders in precision radiation treatment
Elekta, leaders in precision radiation treatment 1951 1995 2007 2008 Versa HD™ Invented stereotactic Introduced first body Leksell Gamma Established VMAT radiosurgery stereotactic system Knife® Perfexion™ 1968 2003 2012 Introduced first dedicated Pioneered CBCT Versa HD™ brain radiosurgery system Le
Slide 25: Track record in variety of cranial indications
Leksell Gamma Knife® Perfexion™ Track record in variety of cranial indications Functional Malignant targets tumors 10% Vascular 7% disorders 43% (single) selective dose delivery 39% Minimum short-to-long-term adverse Benign effect tumors Ability for multiple treatments 47 Cumulative indication
Slide 26: Paddick Conformity Index
Selectivity and related minimum dose to healthy tissue are essential to consider in case of retreatment or proximity to critical structures Case: Four metastases of which one invades the brainstem 49 Leksell Gamma Knife® performance has evolved over the years: increased selectivity and efficiency 0,
Slide 27: Updated multi-institutional study by Ma, et al
Updated multi-institutional study by Ma, et al Int J CARS/April 2014 • Followed same procedure as previous publication • Treatment plans generated for 3, 6, 9 and 12 metastases • Multi-institutional comparison of Cyberknife, Novalis DCA, Leksell Gamma Knife® Perfexion™ and Truebeam FFF 51 “For multi
Slide 28: Future vision for intracranial radiosurgery
ASTRO: future vision for intracranial radiosurgery Expand options for fixation Expand options for image-guided workflow Expand clinical versatility – such as fractionation 53 Works in progress – not available for Sale Leksell Gamma Knife® is the cornerstone of Elekta’s radiosurgery solutions • Inter
Slide 29: Versa HD
55 Versa HD™ Dee Mathieson Senior Vice President, Oncology Business Line Management 56 28
Slide 30: Best in KLAS 2014
Best in KLAS 2014 Radiation Therapy Vendor / Product Performance Score 1 Elekta Elekta Leksell LeksellGamma Knife® Perfexion™ GammaKnife® Perfexion™ 92.8 2 ElektaAgility Elekta Agility™ 91.6 3 Infinity™ ElektaInfinity™ Elekta 88.6 4 Varian TrueBeam™ 85.3 5 Accuray CyberKnife® System 82.3 6 Accuray T
Slide 31: Versatility; Superior for linac-based stereotaxy
Versatility Conventional radiotherapy Advanced stereotactic Versa HD™ precision One Solution. Unlimited Possibilities. 59 Superior for linac-based stereotaxy Stereotactic Cones High resolution MLC Highly conformal beam shaping Rapid leaf speed Extremely low leaf transmission Adaptive Workflows Intra
Slide 32: Clinical application: Lung SABR
Clinical application – lung SABR Throughput: • Up to 60 patients per day • 55Gy in 5 fractions • 10 minute intervals for treatment slots • Treat up to 6 patients per hour • 20-minute time slot for SBRT on the Versa HD™ 61 St James’s University Hospital, Leeds, UK Clinical application – Lung SABR 6 w
Slide 33: Breath-hold gated SBRT; Prostate 78Gy
Breath-hold gated SBRT treatment “ During one breath-hold session of 15 seconds, a complete delivery of 238 MU/1.7 Gy with the dynamic MLC was possible. To deliver a total dose of 12 Gy, 8 breath-hold sessions of 15 seconds each were performed with a total beam on time of less than two minutes.” Pro
Slide 34: Clarity Autoscan prostate motion management
Clarity® Autoscan “Motions up to 8 mm were observed during intra-fraction monitoring.” Marie Fargier-Voiron, Benoit Presles PhD University of Lyon, France 65 Prostate: Non-invasive, no-dose motion management 6 SUP (+) INF (-) 4 Displacements (mm) LT (+) RT (-) ANT (+) POST (-) 2 0 -2 0 100 200 300 4
Slide 35: Versa HD specification; MRI-guided radiation therapy
Versa HD™ – Unmatched specification for stereotaxy • Biological optimization and fast Monte Carlo algorithms - Monaco® • Fastest most accurate collimation available - Agility™ − Better quality plans with more effective/faster modulation − Lowest leakage which is more important than leaf width • High
Slide 36: Current challenges in radiation therapy; Concluding remarks
Current challenges in radiation therapy Current technology (CBCT IGRT) has been exceptionally successful in transforming RT practice and perception. It also has a lot of potential that has yet to be fully exploited However, two main problems will remain: • Image quality − This is not at all sufficie
Slide 37: Strategic choices
Strategic choices • Emerging markets • Product innovation • Software 71 72 36